Validation of anti-aging drugs by treating age-related diseases.
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.
Blagosklonny
Mikhail V
MV
Cancer Center, Ordway Research Institute, Albany, NY 12208, USA.
D000375:Aging / Q000187:drug effects* / Q000473:pathology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D015415:Biomarkers; D002908:Chronic Disease / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D000077185:Resveratrol; D020123:Sirolimus / Q000627:therapeutic use; D013267:Stilbenes / Q000627:therapeutic use; D054928:Validation Studies as Topic
D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D015415:Biomarkers; D007004:Hypoglycemic Agents; D013267:Stilbenes; D008687:Metformin; D000077185:Resveratrol; D020123:Sirolimus